Gecko Biomedical to Advance Next-generation of Tissue Adhesives for Wound Closure by Closing of Series A Financing Round

Paris, France -- Gecko Biomedical, a privately owned medical device company based in Paris that is developing novel biodegradable surgical wound closure solutions, announced the closing of a 8 million INSERT INTO [lzx].[dbo].[tb_new]([id],[type],[title],[source],[personal],[image],[contents],[time],[number]) VALUES (11m) Series A financing round. The financing was co-led by Omnes Capital and CM-CIC Capital Finance, and joined by CapDecisif Management.

Gecko Biomedical develops paradigm-shifting surgical wound closure products that harness revolutionary ‘bio-inspired biodegradable and biocompatible adhesive substances to deliver ‘on- demand wound closure during surgical procedures in the presence of body fluids, such as blood. The Companys products include light-activated adhesive liquid films and patches, both of which improve the safety and efficiency of wound closure inside the body, and are ideally suited for use during minimally invasive (or "keyhole") surgery. The technologies have been successfully assessed in multiple surgical settings in preclinical models, thereby validating the benefits for a wide range of medical applications.

Created in 2013, Geckos rapid development is based on the close relationships between the founders: Bernard Gilly and his iBionext Network; world-leading scientists Robert Langer from the Massachusetts Institute of Technology (Cambridge, MA, USA) and Jeff Karp from the Brigham and Womens Hospital (Boston, MA, USA) both leading experts in the field of bioengineering and regenerative approaches; as well as with Christophe Bancel, member of the iBionext Network and founding CEO of Gecko Biomedical. Jacques Marescaux from the Institute of Research Against Digestive Cancer (Strasbourg, France) an expert in the use of laparoscopy (keyhole surgery) complements this high-profile team.

"Nature provides us with great inspiration for developing solutions to medical challenges, and wound closure is no exception. This is an area of huge importance that has seen minimal innovation in recent years and where we still use sutures and staples, which have many inherent limitations. Looking to nature, our scientists observed adhesive mechanisms that function in challenging but comparable environments and this enabled them to envision completely new solutions for wound closure," said Robert Langer, co-founder and David H. Koch Institute Professor at MIT. "We are proud to see that, through this financing, the innovation born within our laboratories can now be translated into innovative solutions designed to improve patient outcomes and potentially reset the practice of minimally invasive surgery."

Christophe Bancel, founding Chief Executive Officer of Gecko Biomedical, commented: "We have clearly demonstrated the robustness and effective use of our technology pla